Chavin et al. J Immunol 152: 3729-3739, 1994.* |
Harlow et al. Antibodies A Lab Manual pp. 578-581, 1988.* |
Jenkins et al. J Immunol 144: 16-22, 1990.* |
Katz et al. Clin. Immunol. & Immunopath. 55:148-155, 1990.* |
Moscona et al. In Cells & Tissue Culture Willmer, Ed. pp. 60-61, 1965.* |
Schwarz et al. J Immunol 154:5813-5820, 1995.* |
JameWay et al Immuno Biology pp. 2:41-243 and 6:2-6:3, 1994.* |
Defrancesco, The Scientist 1/5, 1998.* |
Bio Whittaker: Adoptive Immunotherapy X-VIVO Product Info, 2002.* |
Cao et al. J. Hematother: and Slam Cell Res. 9:183-194, 2000.* |
Jixum Lin et al. “CD3 and CD2 Ligation Alters CD49d Epitope expression.” Pathobiology : 119-132 (1995). |
R.A.W. Van Lier et al. “Immobolized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes.” Immunology 68: 45-50 (1989). |
Paul Anderson et al. “Crosslinking CD3 with CD2 Using Sepharose-Immobilized Antibodies Enhances T Lymphocyte Proliferation.” Cellular Immunology 115: 246-256 (1998). |
Raymond P. Donnelly and Thomas J. Rogers “Immunosuppression induced by Staphylococcal Enterotoxin B.” Cellular Immunology 72: 166-177 (1982). |
Beverly Z. Packard and Gordon Parry “Bone marrow activation by immobilized antibodies against tumor cells and immunocytes as a potential cancer immunotherapy.” Biochimica et Biophysica Acta. 1224: 395-400 (1994). |
Nguyen et al, Cellular Immunology, 165(1):153-157 (1995). |
Wolf et al, European Journal of Immunology, 24(6):1410-1417 (1994). |
Horwitz et al, Molecular Immunology, 30(11):1041-1048 (1993). |
Chai et al, International Immunology, England, 9(7):935-944 (1997). |